Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study

John M. Bennett, Mary S. Young, Jane L. Liesveld, Elisabeth Paietta, Kenneth B. Miller, Hillard M. Lazarus, Robert D. Marsh, William R. Friedenberg, Hussain T. Saba, F. Ann Hayes, Gordon W. Dewald, Wolfgang Hiddemann, Jacob M. Rowe

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an 'S' phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients. (C) 2001 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalAmerican Journal of Hematology
Volume66
Issue number1
DOIs
StatePublished - Jan 3 2001
Externally publishedYes

Keywords

  • Cytarabine
  • GM-CSF
  • Mitoxantrone
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): An eastern cooperative oncology group study'. Together they form a unique fingerprint.

  • Cite this